Citations

Clear

4847 citation(s) found for "Tu, Eric".

KRAS Promotes GLI2-Dependent Transcription during Pancreatic Carcinogenesis
Sigafoos, Ashley N. , Tolosa, Ezequiel J. , Carr, Ryan M. , Fernández‐Barrena, Maite G. , Almada, Luciana L. , Pease, David R. , Hogenson, Tara L. , Arul, Glancis L. Raja , Mousavi, Fatemeh , Sen, Sandhya , Vera, Renzo E., Marks, David L. , Flores, Luis F. , LaRue-Nolan, Kayla C. , Wu, Chen , Vrabel, Anne M., Sicotte, Hugues , Smyrk, Thomas C. , Zhang, Lizhi , Oberg, Ann L. , Elsawa, Sherine F. , Pin, Christopher L. , Mao, Junhao , Fernández-Zapico, Martín E. , Raja Arul, Glancis L, Bamlet, William R , Sicotte, Hugues , Schenk, Erin L. , Chaffee, Kari G. , Oberg, Ann L , Chevet, Eric , Graham, Rondell P , Hagen, Catherine E , McWilliams, Robert R , Fernandez-Zapico, Martin E , Elsawa, Sherine F , Raja Arul, Glancis Luzeena , Carr, Ryan M , Bamlet, William R. , Rabe, Kari G. , Zaphiropoulos, Peter G. , Chevet, Éric , Graham, Rondell P. , Hagen, Catherine E. , Magliano, Marina Pasca di , McWilliams, Robert R.

Mayo Clinic

Cancer Research Communications | June 19, 2024 | Volume: 4 | Issue: 7 | Pages: 1677-1689

10.1158/2767-9764.crc-23-0464 | PMID 38896052 Get It

Abstract Aberrant activation of GLI transcription factors has been implicated in the pathogenesis of different tumor types including pancreatic ductal adenocarcinoma. However, the mechanistic link with established drivers of this disease remains in part elusive. In this study, using a new genetically engineered mouse model overexpressing constitutively active mouse form of GLI2 and a combination of genome-wide assays, we provide evidence of a novel mechanism underlying the interplay between KRAS, a major driver of pancreatic ductal adenocarcinoma development, and GLI2 to control oncogenic gene expression. These mice, also expressing KrasG12D, show significantly reduced median survival rate and accelerated tumorigenesis compared with the KrasG12D only expressing mice. Analysis of the mechanism using RNA sequencing demonstrate higher levels of GLI2 targets, particularly tumor growth–promoting genes, including Ccnd1, N-Myc, and Bcl2, in KrasG12D mutant cells. Furthermore, chromatin immunoprecipitation sequencing studies showed that in these cells KrasG12D increases the levels of trimethylation of lysine 4 of the histone 3 (H3K4me3) at the promoter of GLI2 targets without affecting significantly the levels of other major active chromatin marks. Importantly, Gli2 knockdown reduces H3K4me3 enrichment and gene expression induced by mutant Kras. In summary, we demonstrate that Gli2 plays a significant role in pancreatic carcinogenesis by acting as a downstream effector of KrasG12D to control gene expression.
Does Operating Volume On-Call Vary by Surgeon? Analysis of On-Call Cases in an Academic Colorectal Practice
Mirande, Maxwell D. , Bews, Katherine A. , Dozois, Eric J. , Mathis, Kellie L. , McKenna, Nicholas P , McKenna, Nicholas P. , Kelley, Scott R.

Mayo Clinic

The American Surgeon™ | June 18, 2024 | Volume: 90 | Issue: 11 | Pages: 3144-3147

10.1177/00031348241262424 | PMID 38870480 Get It

The aim was to determine whether on-call case volumes differ amongst colorectal surgeons, and what cases are performed on-call in an academic colorectal surgery practice. The on-call schedule for the year 2021 of a colorectal surgery practice was analyzed. Details of the case origin and operative details were collected. Average cases performed per call per surgeon were compared. Ten surgeons were included, and average cases per call ranged from .5 to 1.4 with 1.0 the overall average ( P = .007). Analyzing individual pairs, differences existed between the 2 busiest and the least busy on-call surgeon (both P < .05). Most patients operated on-call were admitted via the emergency department (59%), and the most common operations were exams under anesthesia (39%) and bowel resections (33%). On average, 1 on-call case was performed per day. Surgeon on-call volume was similar aside from the busiest and least busy on-call surgeons.
NFS-21. DEMOGRAPHIC, CLINICAL AND IMAGING CHARACTERISTICS OF NEWLY DIAGNOSED OPTIC PATHWAY GLIOMAS ASSOCIATED WITH NF1: RESULTS FROM THE INTERNATIONAL MULTICENTER NF1-OPG NATURAL HISTORY STUDY
Fisher, Michael J. , Listernick, Robert , Liu, Grant, Ferner, Rosalie E. , Lasky-Zeid, Janice, Ullrich, Nicole J. , Stasheff, Steven F., Rosser, T.H.L., Borcher, March, Arden-Holmes, Simone, Flaherty, Maree , Hummel, Trent R. , Motley, Walker, Bielamowicz, Kevin , Phillips, Paul H. , Reginald, Arun, Peragallo, Jason H. , Sato, Aimee , Hogan, Nick, McCourt, Emily A. , Ranka, Milan P., Campen, Cynthia , Beres, Shannon , Stearns, Duncan , Örge, Faruk , O’Halloran, Henry S., Oattes, Julius, Reddy, Alyssa , Brodsky, Michael A., Donahue, Sean P., Blank, Peter M K de , Gutmann, David H. , Heidary, Gena , Bornhorst, Miriam , Rosser, Teena, Bouffet, Éric , Wolf, David S. , El-Dairi, Mays , Mater, David Van , Tarczy‐Hornoch, Kristina , Klesse, Laura J. , Foreman, Nicholas K. , Allen, Jeffrey C. , Moertel, Christopher L. , Areaux, Raymond G. , Crawford, John Ross , Brodsky, Michael, Esbenshade, Adam J. , Cutter, Gary , Avery, Robert A.

Mayo Clinic

Neuro-Oncology | June 18, 2024 | Volume: 26 | Issue: Supplement_4 | Pages: 0-0

10.1093/neuonc/noae064.579 Get It

Abstract BACKGROUND Treatment and clinical management decisions for children with NF1-OPGs remain challenging as most existing data are retrospective and have not included standardized visual outcomes. In this study, we prospectively enrolled newly diagnosed NF1-OPGs and performed standardized neuro-oncology and ophthalmology assessments in order to develop evidence-based guidelines for monitoring and treatment. METHODS Children with NF1-OPG on MRI who were evaluated by both a study ophthalmologist and neuro-oncologist/NF1 expert within 1 month of radiologic diagnosis were eligible for enrollment. All subjects attempted quantitative visual acuity using Teller acuity cards (TAC) as well as ATS-HOTV testing. The neuro-oncologist/NF1 expert provided reasons for obtaining the MRI as well as initiating treatment, if applicable. Descriptive statistics calculated the success rate of acquiring TAC and reasons to obtain the MRI. RESULTS Two-hundred fifty subjects from 22 institutions were enrolled and had at least one visit beyond baseline (Median age 3.1 years, range 0.1–16.8; 53% female). TAC was successfully acquired in both eyes (N=195, 78%) and at least one eye in (N=206, 82%). ATS-HOTV was successfully acquired in both eyes (N=97, 39%) and at least one eye in (N=98, 39%). The two most common reasons to obtain an MRI were screening due to a diagnosis of NF1 (N=99, 39%) and ophthalmologic concern (N=81, 32%). At enrollment, continued observation occurred in a majority of subjects (N=221, 88%) while treatment with chemotherapy was initiated in only 11% (N=29). Twenty-nine (11%) subjects initially observed transitioned to treatment after enrollment (range: 2.5–25 months) thus far. DISCUSSION We present a prospective multicenter study of children with newly diagnosed NF1-OPGs. The ability to acquire quantitative visual acuity was higher than anticipated. The frequency of NF1-OPGs requiring treatment is lower than previously reported. Regression models of clinical and MRI features that prompted immediate treatment with chemotherapy versus observation will be discussed.
NFS-24. TUMOR VOLUME IN NEWLY DIAGNOSED OPTIC PATHWAY GLIOMAS ASSOCIATED WITH NF1 (NF1-OPG): PRELIMINARY RESULTS FROM THE INTERNATIONAL MULTICENTER NF1-OPG NATURAL HISTORY STUDY
Jiang, Zhifan , Parida, Abhijeet , Listernick, Robert , Liu, Grant, Ferner, Rosalie E. , Lasky-Zeid, Janice, Ullrich, Nicole J. , Stasheff, Steven F., Rosser, T.H.L., Arden-Holmes, Simone, Flaherty, Maree , Hummel, Trent R. , Motley, Walker, Bielamowicz, Kevin , Phillips, Paul H. , Reginald, Arun, Peragallo, Jason H. , El-Diari, Mays, Sato, Aimee , Hogan, Nick, McCourt, Emily A. , Ranka, Milan P., Campen, Cynthia , Beres, Shannon , Stearns, Duncan , Örge, Faruk , O’Halloran, Henry S., Brodsky, Michael A., Donahue, Sean P., Oattes, Julius, Reddy, Alyssa , Linguraru, Marius George , Fisher, Michael J. , Avery, Robert A. , Gutmann, David H. , Blank, Peter M K de , Heidary, Gena , Bornhorst, Miriam , Rosser, Teena, Borchert, Mark , Bouffet, Éric , Wolf, David S. , Mater, David Van , Tarczy‐Hornoch, Kristina , Klesse, Laura J. , Foreman, Nicholas K. , Allen, Jeffrey C. , Moertel, Christopher L. , Areaux, Raymond G. , Crawford, John Ross , Brodsky, Michael, Esbenshade, Adam J. , Cutter, Gary

Mayo Clinic

Neuro-Oncology | June 18, 2024 | Volume: 26 | Issue: Supplement_4 | Pages: 0-0

10.1093/neuonc/noae064.582 Get It

Abstract BACKGROUND NF1-OPGs are amorphous tumors involving either single or multiple locations (optic nerve, chiasm, tract) along the anterior visual pathway (AVP). In this prospective study, we investigated how volumetric MRI measures of the AVP as well as other clinical variables are associated with treatment decisions in children with newly diagnosed NF1-OPGs. METHODS Children with newly diagnosed NF1-OPG whose MRI included a T1-weighted volumetric sequence without significant artifact at their enrollment visit were eligible for inclusion. All subjects underwent a quantitative ophthalmic exam to determine if visual acuity (VA) was normal. The neuro-oncologist/NF1 expert determined whether the subject would be observed or undergo treatment at that baseline visit. Volumetric MRI analysis was automatically performed using a deep learning network that measured AVP volume (mm3). Non-parametric group comparisons and multivariable logistic regression models evaluated the impact of age at enrollment, sex, NF1 inheritance type, AVP volume, and VA on the decision for immediate treatment with chemotherapy versus observation. RESULTS One-hundred twenty-three subjects met inclusion criteria. Subjects assigned to observation (N=112, 44% female) and subjects immediately treated with chemotherapy (N=11, 80% female) at enrollment were of similar age (2.7 and 2.8 years, respectively) and inheritance (p &gt; 0.05). Abnormal VA was present more often in the treatment group (46%) compared to the observation group (17%, p &lt;0.001). AVP volume was significantly greater in the treatment group (4,181.1mm3) compared to the observation group (1,819.8mm3, p &lt;0.001). AVP volume, sex, and VA reached significance in univariable regression, however, in the multivariable regression model only the AVP volume (p &lt; 0.001) was significantly associated with treatment initiation. DISCUSSION Children with greater NF1-OPG AVP volumes are treated more often compared with those with lower volumes. Volumetric measures of NF1-OPGs are a valuable metric in understanding treatment patterns and are positioned to help inform clinical decision making.
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated overall survival analysis with 29-month follow-up of NAPOLI 3.
Hussein, Maen , Khan, Gazala , Chandana, Sreenivasa R , Goetze, Thorsten Oliver , Dean, Andrew , Lee, Woo Jin , Hubner, Richard , Paulson, Andrew Scott , Pant, Shubham , Maxwell, Fiona , Pazo-Cid, Roberto , Kišš, Igor , Gállego, Javier , Macarulla, Teresa , Fouchardière, Christelle de la , O’Reilly, Eileen M. , Wainberg, Zev A. , Cutsem, Eric Van , Bekaii‐Saab, Tanios , Pant, Shubham , Melisi, Davide

Mayo Clinic

Journal of Clinical Oncology | June 17, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 4136-4136

10.1200/jco.2024.42.16_suppl.4136 Get It

4136 Background: NAPOLI 3 (NCT04083235, N = 770), a global, randomized, open-label phase 3 study, demonstrated that NALIRIFOX significantly improved overall survival (OS, primary endpoint) and progression-free survival compared with nab-paclitaxel and gemcitabine in patients with untreated mPDAC. Here, we report an updated analysis of OS. Methods: Eligible patients with histopathologically/cytologically confirmed untreated mPDAC were randomized (1:1) to receive liposomal irinotecan 50 mg/m2 + oxaliplatin 60 mg/m2 + leucovorin 400 mg/m2 + 5-fluorouracil 2400 mg/m2 (NALIRIFOX, n = 383) on days 1 and 15 of a 28-day cycle or nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 (Gem+NabP, n = 387) on days 1, 8 and 15 of a 28-day cycle. Randomization was stratified by ECOG performance status, geographic region and presence/absence of liver metastases. An updated OS analysis (data cutoff: 3 October 2023) was conducted. Kaplan–Meier methods were used to estimate median (95% confidence interval [CI]) OS and hazard ratios (HRs [95% CI]) were estimated using stratified Cox proportional hazard models. The difference between groups was tested using a stratified log-rank test. Results: The median follow-up for OS was 28.7 months in the NALIRIFOX arm and 29.7 months in the Gem+NabP arm. At data cutoff, 11 patients were still receiving study treatment, all of whom were in the NALIRIFOX arm. With a total of 673 OS events (NALIRIFOX, n = 328; Gem+NabP, n = 345), median OS was 11.1 months (95% CI 10.0–12.1) in the NALIRIFOX arm compared with 9.2 months (8.3–10.6) in the Gem+NabP arm (HR 0.84 [95% CI 0.72–0.98]; nominal p = 0.026). At 12 months and 18 months, survival rates were 45.6% (95% CI 40.5–50.5) and 26.6% (22.2–31.1), respectively, in the NALIRIFOX arm and 39.6% (34.7–44.5) and 20.0% (16.1–24.1), respectively, in the Gem+NabP arm. Conclusions: In this 29-month follow-up of NAPOLI 3, NALIRIFOX continued to demonstrate improved OS compared with Gem+NabP, with 11 patients still receiving the NALIRIFOX regimen. These data confirm NALIRIFOX as a new possible standard of care and reference regimen for the first-line treatment of patients with mPDAC. Clinical trial information: NCT04083235 .
Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): Minimum 3-year survival follow-up.
Yoon, Harry H. , Raymond, Eric, Hubner, Richard , Shu, Yongqian , Pan, Yueyin , Zhang, Jingdong , Park, Sook Ryun , Kojima, Takashi , Lin, Chen‐Yuan , Li, Liyun , Wu, Hongqian, Peng, Yanyan , Yan, Shican, Kato, Ken , Raymond, Éric , Jiang, Yi , Wyrwicz, Lucjan , Tougeron, David , Ishihara, Ryu , Xu, Jianming

Mayo Clinic

Journal of Clinical Oncology | June 17, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 4032-4032

10.1200/jco.2024.42.16_suppl.4032 Get It

4032 Background: RATIONALE-306 (NCT03783442) is the first global study to investigate anti-programmed cell death protein 1 therapy in combination with different chemotherapy (chemo) options in the first-line (1L) treatment of advanced/metastatic esophageal squamous cell carcinoma (ESCC). At interim analysis (IA), tislelizumab (TIS) plus chemo demonstrated a statistically significant, clinically meaningful improvement in overall survival (OS) versus placebo (PBO) plus chemo, with a manageable safety profile. Here, we report updated efficacy and safety data with minimum 3 years’ follow-up after study unblinding at IA. Methods: Adults with unresectable locally advanced recurrent/metastatic ESCC and no prior systemic treatment for advanced disease were enrolled and randomized (1:1; stratified by region, prior definitive therapy, and investigator [INV]-chosen chemo) to receive TIS 200 mg (Arm A) or PBO (Arm B) IV every 3 weeks plus chemo (platinum plus fluoropyrimidine or platinum plus paclitaxel), until disease progression or intolerable toxicity. The primary endpoint was OS in the intent-to-treat population. Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and duration of response (DoR), all per INV, and safety. Results: In total, 649 patients (pts) were randomized (Arm A, n=326; Arm B, n=323). At a minimum study follow-up of 36.0 months, improvements in OS, PFS, and DoR in Arm A versus B (Table) were maintained relative to the IA. The hazard ratio (HR) for OS with TIS plus chemo versus PBO plus chemo was 0.70 (95% confidence interval: 0.59, 0.83). Similar to the IA, incidences of any-grade (96.6% vs 96.3%) or grade ≥3 (67.0% vs 64.5%) treatment-related adverse events (TRAEs) were comparable between Arms A and B, respectively; treatment-emergent adverse events leading to treatment discontinuation were higher in Arm A (32.1%) versus B (22.1%). In Arm A versus B, respectively, serious TRAEs occurred in 29.9% vs 19.6% of pts; TRAEs leading to death occurred in 1.9% and 1.2%. Conclusions: After minimum 3 years’ follow-up, 1L TIS plus chemo continued to demonstrate clinically meaningful improvements in OS and PFS and durable antitumor response benefit versus PBO plus chemo in pts with advanced/metastatic ESCC, with no new safety signals. Clinical trial information: NCT03783442 . [Table: see text]
University of Washington Quality of Life subdomain outcomes after treatment of sinonasal malignancy: A prospective, multicenter study
Maoz, Sabrina L. , Golzar, Autreen , Hwang, Peter H. , Adappa, Nithin D. , Getz, Anne E., Humphreys, Ian M. , Chan, Erik, Chang, Eugene H. , Jafari, Aria , Kingdom, Todd T. , Kohanski, Michael A. , Lee, Jivianne K., Lazor, Jillian W. , Nabavizadeh, Ali , Adappa, Nithin D. , Patel, Zara M. , Smith, Timothy L. , Storm, Phillip B. , Wang, Marilene B. , Sim, Myung‐Shin , Choby, Garret , Hwang, Peter H , Wang, Eric W , Kuan, Edward C , Humphreys, Ian M , Jafari, Aria , Kingdom, Todd T , Nayak, Jayakar V , Patel, Zara , Smith, Timothy L , Snyderman, Carl H , Beswick, Daniel , Maoz, Sabrina L , Choby, Garret , Adappa, Nithin D. , Geltzeiler, Mathew , Le, Christopher H. , Pinheiro‐Neto, Carlos , Fischer, Jakob L. , Abuzeid, Waleed M. , Nayak, Jayakar V. , Resnick, Adam , John, Maie A. St. , Suh, Jeffrey D. , Beswick, Daniel M.

Mayo Clinic

International Forum of Allergy & Rhinology | June 17, 2024 | Volume: 14 | Issue: 10 | Pages: 1568-1581

10.1002/alr.23386 | PMID 38884276 Get It

AbstractPurposeSinonasal malignancies (SNMs) adversely impact patients’ quality of life (QOL) and are frequently identified at an advanced stage. Because these tumors are rare, there are few studies that examine the specific QOL areas that are impacted. This knowledge would help improve the care of these patients.MethodsIn this prospective, multi‐institutional study, 273 patients with SNMs who underwent definitive treatment with curative intent were evaluated. We used the University of Washington Quality of Life (UWQOL) instrument over 5 years from diagnosis to identify demographic, treatment, and disease‐related factors that influence each of the 12 UWQOL subdomains from baseline to 5 ‐years post‐treatment.ResultsMultivariate models found endoscopic resection predicted improved pain (vs. nonsurgical treatment CI 2.4, 19.4, p = 0.01) and appearance versus open (CI 27.0, 35.0, p < 0.001) or combined (CI 10.4, 17.1, p < 0.001). Pterygopalatine fossa involvement predicted worse swallow (CI −10.8, −2.4, p = 0.01) and pain (CI −17.0, −4.0, p < 0.001). Neck dissection predicted worse swallow (CI −14.8, −2.8, p < 0.001), taste (CI −31.7, −1.5, p = 0.02), and salivary symptoms (CI −28.4, −8.6, p < 0.001). Maxillary involvement predicted worse chewing (CI 9.8, 33.2; p < 0.001) and speech (CI −21.8, −5.4, p < 0.001) relative to other sites. Advanced T stage predicted worse anxiety (CI −13.0, −2.0, p = 0.03).ConclusionsSurgical approach, management of cervical disease, tumor extent, and site of involvement impacted variable UWQOL symptom areas. Endoscopic resection predicted better pain, appearance, and chewing compared with open. These results may aid in counseling patients regarding potential QOL expectations in their SNM treatment and recovery course.
Multi‐center study on sellar reconstruction after endoscopic transsphenoidal pituitary surgery
Ali, Hawa M. , Leland, Evelyn M. , Stickney, Emily, Lohse, Christine M. , Iyoha, Ehiremen, Valappil, Benita, Filimonov, Andrey , Goetschel, Kaitlin , Young, Sarah C. , Shahin, Maryam N. , Sanusi, Olabisi , Sonfack, Davaine Joel Ndongo , Champagne, Pierre‐Olivier , Zwagerman, Nathan T. , Gardner, Paul A. , Zenonos, Georgios A. , Link, Michael J. , Peris‐Celda, Maria , Stokken, Janalee K., Stokken, Janalee K. , Wang, Eric W , Snyderman, Carl H , Van Gompel, Jamie, Choby, Garret , Carlson, Matthew L , Nadeau, Sylvie , Geltzeiler, Mathew , Gompel, Jamie J. Van , Choby, Garret , Pinheiro‐Neto, Carlos

Mayo Clinic

International Forum of Allergy & Rhinology | June 17, 2024 | Volume: 14 | Issue: 10 | Pages: 1558-1567

10.1002/alr.23382 | PMID 38884280 Get It

AbstractIntroductionSurgical techniques for sellar reconstruction include no reconstruction, use of synthetic materials, autologous grafts, and/or vascularized flaps. The aim of this study was to conduct a multi‐center study comparing the efficacy and postoperative morbidity associated with different sellar reconstruction techniques.MethodsA retrospective chart review of patients who underwent endoscopic transsphenoidal surgery for pituitary tumors from five participating sites between January 2021 and March 2023 was performed. The variables included demographics, tumor characteristics, reconstruction technique, postoperative cerebrospinal fluid leak (CSF) leak, and 22‐item Sino‐Nasal Outcome Test (SNOT‐22) scores. Comparisons of postoperative complications, SNOT‐22 scores, and duration of surgery by type of onlay reconstruction were evaluated using Fisher's exact test, analysis of variance, and Kruskal‒Wallis test.ResultsFive hundred and one patients were identified. The median tumor size was 2.1 cm, and 64% were non‐functioning. Intraoperative CSF leak was identified in 38% of patients. A total of 89% of patients underwent onlay reconstruction: 49% were reconstructed with mucosal grafts, 35% with nasoseptal flaps, and 5% with other onlay techniques. Nasoseptal flaps were utilized more frequently in the setting of giant pituitary adenomas (>3 cm), medial cavernous sinus wall resection, and high‐flow intraoperative CSF leaks. Cases who utilized mucosal grafts had an overall shorter operating time (median: 183 min vs. 240 min; p < 0.001). Five postoperative CSF leaks were identified, and therefore, statistical analysis could not be performed for this complication.ConclusionThe effectiveness and morbidity of different sellar reconstruction techniques are comparable. Vascularized flaps were utilized more frequently in the setting of larger tumors and high‐flow intraoperative CSF leaks.
Microfluidic Digital Immunoassay for Point-of-Care Detection of NT-proBNP from Whole Blood
Chen, C.-H. , Zhou, Xiaoyan , Snozek, Christine L.H. , Chen, Chao , Zhou, Xiaoyan , Snozek, Christine Lh, Wang, Shaopeng , Porter, Ryan, Yang, Eric H. , Wang, Shaopeng

Mayo Clinic

Analytical Chemistry | June 15, 2024 | Volume: 96 | Issue: 26 | Pages: 10569-10576

10.1021/acs.analchem.4c01046 | PMID 38877973 Get It

Percutaneous Coronary Intervention in Acute Myocardial Infarction Patients with Cardiogenic Shock
Forst, Beani, Smyth, Philip J, Kanaan, Christopher , Acharya, Deepak , Smyth, Philip , Forst, Beani, Yang, Eric H. , Lee, Kwan

Mayo Clinic

Journal of the Hong Kong College of Cardiology | June 14, 2024 | Volume: 31 | Issue: 4 | Pages: No page available

10.55503/2790-6744.1533 Get It

Cardiogenic shock is the most common cause of mortality in patients with acute myocardial infarction with an increase in incidence over the last 15-years. Recent classification systems of cardiogenic shock (CS) have improved categorization of patients into subsets of acuity and begun to integrate phenotypes and etiologies in addition to risk modifiers. Early revascularization with PCI or CABG has been the most important advance in the management of AMI-CS patients with improvements in survival. Despite this initial progress, mortality remains high at approximately 40%, with a significant proportion of patients dying of neurological causes, especially in the cohort with cardiac arrest and multi-organ dysfunction despite cardiac recovery. Mechanical circulatory support devices are an attractive strategy to ameliorate the cardio-metabolic spiral but have thus far failed to show survival benefits in randomized trials during revascularization of AMI-CS patients with IABP and ECMO use, although many aspects of their use have yet to be studied, including their role as part of an escalation or bridging strategy along the continuum of CS care. Randomized trials in Impella percutaneous LVAD use are pending. Cardiac arrest patients represent an important cohort with specific challenges of care and familiarity with management including the use of mechanical CPR devices, temperature optimization, MCS use and pharmacotherapy issues are critical to successful outcomes.